Pfizer Terminates Hemophilia A Gene Therapy Partnership with Sangamo
Pfizer ends its hemophilia A gene therapy partnership with Sangamo, impacting the future of giroctocogene fitelparvovec. Despite positive Phase III results, market challenges led to Pfizer’s withdrawal, leaving Sangamo to seek new avenues for the promising therapy.
Pfizer Terminates Hemophilia A Gene Therapy Partnership with Sangamo Read More »